


T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company
Rhode Island Medical Journal, February 2013. rimed.org/rimedicaljournal/2013-02/2013-02-19-bio-epivax.pdf
Highly Immunogenic Vaccine For Prevention and Therapy of Malignant Mesothelioma
